Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?

To: William Strop who wrote (1224)	3/4/2000 10:08:00 PM
From: Scott H. Davis	Read Replies (2) \| Respond to of 1972

A plea for therapeutic help. A member of my church has stage II Hodgkins. Does anyone know of any Phase III open label trials that they have followed that they find very positive based on the data and/or technology, especially non-cytotoxic? (Or possible double blind where there has been a precedent for companionate use?) We live in Carbondale IL, a small town in the midst of an economically depressed, fairly sparely populated area, thus not exactly a center of oncology expertise. Any help will be greatly. Please feel free to reply via public post, private post, or private e-mail (sdavis@midwest.net) Thanks, Scott

To: William Strop who wrote (1224)	3/12/2000 2:32:00 PM
From: Kash Khorasani	Respond to of 1972

The following is posted in Yahoo's HGSI board. Hoping that the results are good for VICL!! Kash ------------------------------------------------------- Growth Factors Used to Stimulate the Growth of New Blood Vessels Offer Both Opportunities and Challenges EMBARGOED FOR RELEASE March 12, 2000 Time of Presentation or News Conference (PST) Contact: Melanie Caudron or Beth Cassady March 12-15: 714-765-2021 After March 15: 301-897-2628 (not for publication) ACC 49th Annual Scientific Session News Conference Highlights Sunday, March 12, 2000 (ANAHEIM, CALIF.)?One of the most active research areas in the treatment of advanced heart disease involves the use of growth factors to stimulate angiogenesis?the growth of new blood vessels?within the heart. Five studies being presented at the American College of Cardiology 49th Annual Scientific Session in Anaheim, Calif., March 12?15, 2000, explore both the opportunities and challenges associated with these growth factors. The studies will be the subject of a news conference on March 12 at 10:30 a.m. Researchers at Beth Israel Deaconess Medical Center in Boston are testing a growth factor called recombinant fibroblast growth factor (rFGF-2), which has wider- ranging properties than other growth factors. The investigators also note that, in theory, because rFGF-2 works on many cell types, it may be a more effective growth factor than others. The FGF-2 Initiating Revascularization Support Trial (FIRST) will determine whether patients who receive the growth factor improve their exercise ability, which would suggest that the treatment had spurred new vessel growth in their hearts. (Presented on March 12 at 9:00 a.m.) Dr. Jeffrey Isner of Tufts Medical School in Boston will also present the results of a study, VEGF-2 Gene Transfer for Myocardial Ischemia, which was recently halted by the Food and Drug Administration. In another study (#1157-50), researchers at the University of California, San Francisco, and Stanford University used mice to explore the effects of myoblast-mediated expression of recombinant human vascular endothelial growth factor (VEGF), an angiogenic factor that has been shown to improve myocardial blood flow and function in animals. Finding that unregulated overexpression of VEGF was associated with death, tumors, and failure to thrive, they emphasize the importance of regulating expression when VEGF is used for therapeutic angiogenesis. (Presented on March 14 at 1:00 p.m.) Copyright ¸ 2000 American College of Cardiology